PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest
Metrics: PDF 1340 views | HTML 1314 views | ?
Li Huang1,2, Yang Peng1,2, Guangzheng Zhong1,2, Weibin Xie1,2, Wen Dong1,2, Bo Wang1,2, Xu Chen1,2, Peng Gu1,2, Wang He1,2, Shaoxu Wu1,2, Tianxin Lin1,2 and Jian Huang1
1 Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
Tianxin Lin, email:
Jian Huang, email:
Keywords: bladder cancer, PBRM1, cell cycle, cyclin B1
Received: February 03, 2015 Accepted: April 03, 2015 Published: April 19, 2015
Growing evidence indicates that dys-regulation of PBRM1 contributes to tumorigenesis. However, little is known about the biological function of PBRM1 in the development or progression of bladder cancer. In this study, we aimed to elucidate the pathophysiological role of PBRM1 in bladder cancer. We assessed the expression of PBRM1 in 64 bladder cancer tissue samples with matching normal tissues. We explored the biological functions of PBRM1 both in vitro and in vivo. Mutational status of PBRM1 was analyzed. Effect of PBRM1 on cell cycle was evaluated. qRT-PCR and Western blot were carried out to evaluate the expression of cyclins affected by PBRM1. Our results showed that PBRM1 expression was significantly reduced in bladder cancer cells and tissues compared to their normal counterparts. The reduced expression of PBRM1 was associated with advanced tumor stage, low differentiation grade and worse patient outcome. Further functional analysis demonstrated that PBRM1 suppressed bladder cancer cell proliferation, migration, colony formation in vitro and tumorigenicity in vivo. Genetic alteration analysis showed no amino-acid sequence altering mutations. We found that PBRM1 could block the G2/M transition by repressing cyclin B1. Our data indicated that PBRM1 functions as a tumor suppressor in bladder cancer by repressing cyclin B1 expression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.